Diabetes research: Are we getting anywhere?

CMAJ. Canadian Medical Association Journal

Volumn 155, Issue 9, 1996, Pages 1271-1274

  Zinman, Bernard ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c 3CCRW845   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

AUTOIMMUNITY; CLINICAL RESEARCH; DIABETES MELLITUS; EDITORIAL; INSULIN TREATMENT; PATHOPHYSIOLOGY;

EID: 0029831708     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Editorial

References (18)

1. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922;12:141-6.
2. Palmer JP. Predicting IDDM. Diabetes Rev 1993;1:104.
3. DeFronzo RA. The triumvirate: ß-cell, muscle, liver. A collision responsible for NIDDM [Lilly lecture 1987]. Diabetes 1988;37:667-87.
4. White MF, Kahn CR. The insulin signaling system [review]. J Biol Chem 1994;269:1-4.
5. Fajans SS, Bell GI, Bowden DW. MODY: a model for the study of the molecular genetics of NIDDM. J Lab Clin Med 1992;119:206-10.
6. Reaven GM. Role of insulin resistance in human disease [Banting lecture 1988]. Diabetes 1988;37:1595-607.
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
8. 11) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-83.
9. The DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991;90:450-9.
10. UK Prospective Diahetes Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34:877-90.
11. Brownlee M. Advanced products of non-enzymatic glycosylation and the pathogenesis of diabetic complications. In: Rifkin H, Porte D Jr, editors. Ellenberg and Rifkin's diabetes mellitus: theory and practice. 4th ed. New York: Elsevier, 1990:279.
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. [published erratum appears in N Engl J Med 1993;330:152]. N Engl J Med 1993;329:1456-62.
13. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk ot cardiovascular events. Clin J Cardiol 1996;12:127-37.
14. The Canadian - European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988;37:1574-82.
15. DPTI-1 Study Group. The Diabetes Prevention Trial-Type 1 diabetes (DPT-1): implementation of screening and staging of relatives. Transplant Proc 1995;27:3377
16. Elliott RB, Pilcher CC, Stewart A, Fergusson D, McGregor MA. The use of nicotinamide in the prevention of type 1 diabetes. Ann N Y Acad Sci 1993;696:333-41.
17. Gerstein HC. Cow's milk exposure and type 1 diabetes mellitus. A critical overview of the clinical literature [review]. Diabetes Care 1994;17:13-9.
18. Zinman B. The physiologic replacement of insulin. An elusive goal [review]. N Engl J Med 1989;321:363-70.